Develops neurology and psychiatry treatments targeting the serotonin system, focusing on mood disorders.
Protagenic Therapeutics, Inc. is a pioneering biopharmaceutical firm based in New York, New York, specializing in the discovery and advancement of novel therapeutics targeted at addressing stress-related neuropsychiatric and mood disorders. Central to its research efforts is PT00114, the company's flagship compound, which represents a synthetic variant of teneurin carboxy-terminal associated peptide. This endogenous brain signaling peptide has shown promise in attenuating hyperactive stress responses within the brain.
Founded on a commitment to innovation and scientific excellence, Protagenic Therapeutics is dedicated to developing transformative treatments that can significantly improve the quality of life for patients suffering from various neuropsychiatric conditions. The company's focus on understanding and modulating brain mechanisms associated with stress underscores its mission to deliver impactful therapeutic solutions.
With a strategic location in New York City, Protagenic Therapeutics is well-positioned within a vibrant biotech hub to drive forward its research and development initiatives. Through collaboration with leading scientific minds and institutions, the company continues to advance its pipeline of innovative therapies aimed at addressing the complex challenges of stress-related disorders.